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EDITORIAL REVIEW
Acute cyclosporine nephrotoxicity—Prototype for a renal
membrane signalling disorder
The past decade has seen the explosive emergence of new
information and understanding regarding mechanisms involved
in transmembrane signal transduction [1]. More recently, it has
been appreciated that a large number of disease states represent
disorders of normal signal transduction processes. Of particular
interest has been the recognition that numerous oncogene
products represent abnormal or overexpressed versions of
components in normal mitogenic signaling pathways. It is now
increasingly apparent that a number of renal diseases also
represent disorders of transmembrane signal transduction. The
aim of this editorial is to use the example of acute cyclosporine
nephrotoxicity as a prototype example for such a renal mem-
brane signalling disorder.
Clinical and pathophysiologic features of acute cyclosporine
nephrotoxicity
The potential full utility of cyclosporine in the prevention of
rejection in organ transplantation, and in a number of other
therapeutic applications, is chiefly limited by the toxicity of this
agent [2, 3]. The principal limiting forms of toxicity are neph-
rotoxicity often with accompanying hypertension. Two forms
of nephrotoxicity have been recognized. The first is an acute
decrement in glomerular filtration rate and renal blood flow,
which is reversible upon reduction in dosage or withdrawal of
the drug. The second form is a chronic and inexorable attrition
of nephron function following chronic exposure. The exact
relationship between the two forms of toxicity remains debat-
able. This manuscript addresses specifically acute cyclosporine
nephrotoxicity as it is this model which may serve as a
prototype for a renal transmembrane signaling disorder. Al-
though there is some evidence indicating that when sustained,
the vasculopathy involved in the acute phase may eventuate in
the chronic form of tubulointerstitial toxicity, there may well be
additional mechanisms which are more important and indepen-
dent of hemodynamic factors. These include enhanced collagen
production [4, 5], and disruption of mitochondrial membrane
integrity and hence function in cells of the proximal tubule [6].
Regardless of whether acute cyclosporine nephrotoxicity
progresses to the chronic form or not, acute cyclosporine
nephrotoxicity limits the application of cyclosporine early in the
course of transplantation, particularly in the case of cadaveric
kidney transplants given the high incidence of early graft
dysfunction, and may also prove to be the key limiting factor in
the use of cyclosporine as a chemosensitizing agent in cancer
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chemotherapy (see below). In any case, this editorial review
will confine itself to a consideration of the possible cellular
mechanisms involved in the pathophysiology of the acute lesion
in the context of serving as a prototype for a renal transmem-
brane signaling disorder.
A number of clinical and whole animal studies have investi-
gated the physiologic basis for acute cyclosporine nephrotox-
icity. The administration of a single oral dose of cyclosporine to
normal volunteers was shown to cause a decrement in both
inulin and paraaminohippurate (PAH) clearance with a dispro-
portionate decrease in the latter indicating a rise in filtration
fraction [7]. Animal studies have confirmed a vasoconstrictor
effect of cyclosporine at the whole kidney level [8—10]. At least
five micropuncture studies have evaluated the effect of cyclos-
porine on the determinants of glomerular filtration rate at the
single nephron level [11—15]. All of these studies were in
agreement in showing that cyclosporine markedly augmented
the glomerular vasoconstrictor response to vasoactive hor-
mones. There were some differences in the predominant site of
enhanced glomerular vasoconstriction [preglomerular vs. intra-
glomerular (Kf) vs. post-glomerular], depending upon the par-
ticular animal model, dosage regimen, and state of salt balance
at the time of study. In most of the studies, the vasoconstrictive
effects of cyclosporine either required or were enhanced by the
input of vasoactive hormones known to modulate renal and
glomerular resistance (vasopressin, angiotensin II, catechol-
amines). Most recently it has been shown that endothelin is
released from glomerular endothelial cells, its levels are aug-
mented following cyclosporine administration, and that cyclos-
porine-induced reduction in glomerular filtration rate can be
ameliorated through endothelin blockade by use of endothelin
antibody [15—19]. Measurements of extrarenal hemodynamics
have demonstrated parallel increases in systemic vascular re-
sistance which accounts at least in part for concomitant cyclos-
porine-induced hypertension [20]. In a recent study in heart
transplant recipients and patients with myasthenia gravis, cy-
closporine administration was shown to increase sympathetic
nerve activation; cardiac denervation seems to enhance this
effect, perhaps because of the ventricular baroreceptor dener-
vation [21]. The work of Xue et a! have demonstrated that
cyclosporine can directly induce contraction in vascular smooth
muscle prepared from rat thoracic aorta ring segments, perhaps
by inducing release of norepinephrine from adrenergic nerve
terminals [22].
Development of experimental approach to investigating the
vasoconstrictor action of cyclosporine at the cellular and
molecular level
Given these findings, a number of laboratories set out to
investigate the cellular and molecular mechanisms involved in
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cyclosporine-induced enhancement of vasoconstrictor hormone
action. Two related in vitro model systems have been used
extensively, namely the glomerular mesangial cell and the
vascular smooth muscle cell in culture. Use of the mesangial
cell is motivated by the finding that cyclosporine markedly
reduced glomerular ultrafiltration coefficient, which is in part
regulated by the contractile state of the glomerular mesangium
[11—13]. The glomerular mesangial cell in culture also has been
a well-characterized analogue of the contiguous vascular
smooth muscle surrounding the afferent and efferent arteriole as
well as vascular smooth muscle cells in the extra-renal circula-
tion [23, 24]. Use of vascular smooth muscle cells in culture is
motivated by the aforementioned finding of hypertension as an
accompaniment of cyclosporine nephrotoxicity [3, 201. In fact,
in heart transplant recipients cyclosporine appears to have
increased the incidence of hypertension from 20 to 90% [21]. In
both the in vitro mesangial and smooth muscle cell systems, the
transmembrane signal transduction mechanisms involved in the
action of a large variety of vasoconstrictor hormones has been
thoroughly studied, thus allowing investigation of potential
perturbations in these normal signal transduction responses
induced by cyclosponne.
Effect of cyclosporine on calcium signalling response
A key step in the signal transduction response responsible for
initiating the contractile response to vasoconstrictor hormones
in vascular smooth muscle and mesangial cells, is a rise in
cytosolic calcium which can be monitored by loading cells with
calcium-sensitive fluorescent probes such as fura—2 and indo—l
[25, 26]. The rise in cytosolic calcium is a consequence of
activation of phospholipase C with resultant inositol trisphos-
phate-mediated release of calcium from intracellular stores,
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Fig. 2. Cyclosporin A concentration dependance for enhancement of
peak [Ca'- response. Shown are the peak ECa2i responses to 30 nM
vasopressin in cells treated with the indicated concentrations of CsA for
90 minutes, expressed as a percentage of the corresponding response in
vehicle-treated cells. Each data point represents the mean SE of
determinations from 6 coverslips in 2 separate experiments. Adapted
with permission from reference [39].
followed by calcium influx from the external environment
[25—29]. Features of the calcium release process include inter-
mediacy of a GTP-binding protein [25], negative feedback
modulation by protein kinase C [29—33], and modulation by
membrane potential [34]. An additional feature is the synergis-
tic interaction that occurs with exposure to submaximal con-
centrations of different agonists, with heterologous desensitiza-
tion following maximally stimulating concentrations of these
agonists [35J. The effect of cyclosporine on this calcium signal-
ing response has been examined using either calcium-sensitive
fluorescent probes or using calcium isotopic flux measure-
ments. Responses to a variety of different vasoconstrictor
agonists including endothelin have been examined in several
different laboratories using both mesangial and vascular smooth
muscle cells in culture with congruent results [26, 36—41]. In one
study [39] preincubation of mesangial cells with cyclosporine
resulted in a small but significant increase in basal cytosolic
calcium, a very marked (3- to 4-fold) augmentation of the peak
rise in cytosolic calcium following vasoconstnctor addition and
in the sustained phase of the response following the cytosolic
calcium peak when external calcium was present in the medium
at the time of agonist addition (Fig. 1). When extracellular
calcium was not present at the time of addition of the vasocon-
strictor agent only enhancement of the peak calcium rise was
observed [24, 40]. The concentration dependence for cyclospo-
rifle induced enhancement of calcium signalling is shown in
Figure 2. A threshold effect occurred at a cyclosponne concen-
tration of approximately 200 ng/ml with a maximum effect
occurring at a concentration of 1 pg/ml. These concentrations
correspond approximately to those which are associated with
acute nephrotoxicity in vivo.
One interpretation of these observed effects of cyclosporine
is to postulate that cyclosporine increases membrane calcium
permeability, thereby increasing total cell calcium [42]. Since
most of this increment in total cell calcium is sequestered into
stores, it reveals itself predominantly as an increase in the peak
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Fig. 1. Representative tracings illustrating the effects of cyclosporine
on the [Ca'-] responses to vasopressin, Mesangial cells on cover slips
were pre-incubated with vehicle (A); or 4 sg/ml CsA (B) and Fura-2AM
for 90 minutes prior to recording the calcium transient response to 30
tIM vasopressin. Adapted with permission from reference [39].
Fig. 3. Effect of CsA on AVP stimulated
45Ca'- efflux in mesangial cells. Cells were
preincubated with CsA or an equivalent
volume of cremophore from 10 minutes at
37°C prior to the start of the experiment. The
incubation medium (PSS) contained
cremophore CsA throughout the entire
experiments. AVP l0_8 M was added: (0)
control, N = 5; (•) CsA 5 g/ml, N 4; (A)
180 CsA 10 g ml, mean SEM; *P < 0.05,
<0.01, < 0.002 versus control. Adapted
with permission from reference [361.
Fig. 4. Proposed effect of cyclosporine on
mesangial cell Ca2 homeostasis. See text for
details. Abbreviations are: R' vasopressin
receptor; IP, inositol trisphosphate receptor.
calcium response to a calcium-mobilizing ligand, which reflects
predominantly release from intracellular stores and occurs
independent of extracellular calcium. In contrast, the sustained
phase of the response represents extracellular calcium-depen-
dent influx, and therefore would be affected by the absence of
extracellular calcium. Indeed, this formulation has been exam-
ined using calcium isotopic flux measurements. These studies
have shown that cyclosporine increases both vasoactive hor-
mone-stimulated calcium influx and effiux in mesangial cells and
vascular smooth muscle cells in culture (Fig. 3) [36, 37]. The
effect of cyclosporine to enhance calcium efflux pathways
excludes inhibition of calcium extrusion mechanisms as the sole
explanation for an enhanced rise in cytosolic calcium and
supports a direct effect on cell membrane calcium permeability
as a possible mechanism for the observed perturbation in
calcium signaling (Fig. 4). Other possible explanations for an
augmented cytosolic calcium signal include: Enhanced sensitiv-
ity of the 1P3 receptor; a greater calcium content of the IP
sensitive store (due to enhanced calcium ATPase dependant
uptake, and/or diminished calcium leak with resultant greater
buffering capacity); recruitment of additional stores as a source
of IP sensitive release; diminished reuptake of calcium back
into 1P3 sensitive or other stores following agonist stimulation;
enhanced calcium-mediated calcium release following the initial
IP sensitive release [431; diminished calcium buffering capacity
of the cytosol. Future studies are needed to evaluate these
possibilities. No compelling evidence has accrued that en-
hanced production of inositol trisphosphate or modulation of
protein kinase C makes a contribution to enhanced calcium
signalling. Furthermore, in recent studies, using a surrogate
system, it was shown that upregulation of phospholipase C-)'
was in itself not sufficient to alter calcium responses, making it
unlikely that modulation occurs at this level [44]. Rather, it is
more likely that the effect of cyclosporine can be explained by
accumulation of the agent in the lipid bilayer and perturbation
of lipid protein interactions which govern membrane calcium
transport. In this regard, it is of note that pre-incubation, rather
than simultaneous administration, was necessary to demon-
strate both the effect of cyclosporine on calcium signaling and
contraction of mesangial and vascular smooth muscle cells. Of
Skorecki et a!: Acute cyclosporine nephrotoxicity 3
AVP
,08 M
I
5.0
4.0
3.0
2.0
1.0
**
—120 —60 0 60 120
Time, seconds
Ca2 Ca2
Control CsA
4 Skoreckiet al: Acute cyclosporine nephrotoxicity
Fig. S. Working model for sequential
activation of phospholipase C and
Phospholipase A2 in mesangial cell
arachadonic acid release. See text for details.
Abbreviations are: VP, vasopressin; PLC,
phospholipase C; PLA2, phospholipase A2;
EGF, epidermal growth factor; 1P3, inositol
trisphosphate; DAG, diacylglycerol; C-kinase,
protein kinase C; FA, fatty acid; AA,
arachidonic acid.
interest, the effect of cyclosporine to enhance calcium signaling
responses has been noted in several cell types (vascular smooth
muscle cells, mesangial cells, and hepatocytes) but is not
universally found in all cell types (such as lymphocytes [45, 46])
possibly reflecting different lipid composition of the membranes
or alternatively the presence or absence of more specific
transmembrane calcium conductive pathways affected by cy-
closporine. The failure of acute administration of the calcium
channel blocker verapamil to alter this effect of cyclosporine on
calcium signalling in vitro suggests an effect on membrane
permeability other than opening of voltage sensitive calcium
channels despite the fact that calcium entry blockers are
effective in ameliorating cyclosporine-induced hypertension in
vivo [36, 37]. It should be noted that an increase in intracellular
calcium due to altered membrane permeability has also been
implicated as the underlying biochemical defect in a large
subgroup of patients with low renin hypertension and reduced
serum-ionized calcium [47]. Cyclosporine may mimic this bio-
chemical defect and thus serve as a model for studying the
pathogenesis of this form of hypertension.
Effects of cyclosporine on prostaglandin production
It is now widely appreciated that normal regulation of the
glomerular microcirculation depends on a balance between
calcium-mediated vasoconstriction and the offsetting effect of
vasodilatory eicosanoids [48]. Withdrawal of the latter influ-
ences results in augmented vasoconstriction, an effect which
has been demonstrated in multiple model systems ranging from
the contractile response of cultured mesangial cells and isolated
glomeruli in vitro to in vivo responses in experimental animals
and in clinical settings. In the absence of cellular infiltration the
principal eicosanoid products in the glomerular microcircula-
tion are P012 in humans and POE2 in rodent species [49]. The
rate-limiting step in the elaboration of these eicosanoids is the
release of arachidonic acid from membrane phospholipids
through the action of phospholipases, followed by conversion
of arachidonic acid to prostaglandin products through the action
of cyclo-oxygenase [5]. The phospholipid pathways for release
of arachidonic acid have been extensively investigated using the
mesangial cell in culture as a model system. The very same
vasoactive hormones which stimulate phospholipase C and
raise intracellular calcium also result in the release of araehi-
donic acid. Furthermore, growth factors to which the glomer-
ular microcirculation is exposed (such as epidermal growth
factor), synergistically and markedly augment arachidonic acid
release in response to calcium mobilizing hormones or pharma-
cological probes [30, 5 1—561.
Recent investigations have elucidated the detailed phospho-
lipid pathways involved in hormone and growth factor-stimu-
lated arachidonic acid release using the mesangial cell in culture
as a model system [5 1—561. These studies revealed that a rise in
intracellular calcium which can occur as a consequence of
phospholipase C activation, is both necessary and sufficient for
activation of phospholipase A2, which in turn releases arachi-
donic acid from the sn-2 position of membrane phospholipids.
The same inositol phospholipids which are substrates for phos-
pholipase C-mediated release of inositol trisphosphate are rel-
atively enriched in arachidonic acid [54]. However, the full
extent of phospholipase A2 activation appears to require the
further input of protein kinase C action (also a consequence of
phospholipase C activation) and growth factor stimulation.
Growth factor stimulation of phospholipase A2 is itself indepen-
dent of coupling of the growth factor receptor to phospholipase
C, but does require a concomitant rise in intracellular calcium
and is likely mediated through the action of a GTP binding
protein [57, 58]. The intrinsic tyrosine kinase activity of the
growth factor receptor, at least when stimulated by EGF, is
necessary for stimulation of PLA2 [52], but this has not been
investigated for other agonists. It has not yet been determined
whether phospholipase A2 is itself directly phosphorylated, or
alternatively whether another closely associated modulatory
protein is phosphorylated (Fig. 5).
Given the importance of the counterbalancing effect of va-
sodilatory prostaglandins to the determination of net glomerular
microcirculatory tone, it was important to consider the effects
of cyclosporine on these phospholipid pathways responsible for
arachidonic acid release. This is especially the case, since, as
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Fig. 6. Effect of GsA on phospholipase activity in mesangial cells. CsA
pretreatment () caused a significant reduction in the vasopressin
stimulatable '4C-arachidonate counts measured as free fatty acid (FFA)
versus control (E), There was, however, no effect on the production of
'4C-arachidonate labeled diacyiglycerol (DAG). Adapted with permis-
sion from reference [401.
was already noted, cyclosporine augments the calcium signal-
ling response to vasoconstrictor hormones and a rise in intra-
cellular calcium is both necessary and sufficient for phospholi-
pase A2 activation. Therefore, it was conceivable that enhanced
intracellular calcium signaling responses might well be offset by
concomitant enhancement of prostaglandin production. When
this was investigated, it was actually found that cyclosporine,
through a distinct mechanism inhibited both basal and hormone
stimulated prostaglandin production in the mesangial cell and in
vascular smooth muscle cells in culture [40, 59—61]. Cyclospo-
rine has been shown not to affect the conversion of added
exogenous arachidonic acid to prostaglandins, suggesting an
effect on the arachidonic acid release step [61]. Indeed, this was
confirmed using labeling of membrane phospholipids with '4C-
arachidonic acid, followed by measurement of hormone-stimu-
lated release of label in non-esterified fatty acid and diacylglyc-
erol (Fig. 6). The results of these experiments demonstrated a
significant inhibition of release of free arachidonic acid with no
effect on diacylglycerol [40]. These results point to a separate
action of cyclosporine on phospholipase A2 with no effect
(either inhibitory or stimulatory) on phospholipase C. Indeed,
in recent preliminary studies, cyclosporine was shown to inhibit
directly phospholipase A7 enzymatic activity in a cell free
extract derived from mesangial cells using exogenous phospho-
lipid substrate [611. In this study, both in terms of extent of
inhibition (40 to 50%) and cyclosporine concentration depen-
dence (in the range of 1 p.g!ml), there was excellent congruency
between the inhibition effect on prostaglandin production,
arachidonic acid release from the intact cell, and inhibition of
phospholipase A2 activity.
Inhibition of prostaglandin production by cyclosporine has
also been described in other experimental preparations (such as
isolated glomeruli [62], endothelial cell preparations [63], etc.).
Other perturbations in arachidonic acid metabolism have been
described. Although thromboxanes are not a prominent ei-
cosanoid product of the glomerular microcirculation, in the
absence of an inflammatory cellular infiltrate, enhanced produc-
tion of vasoconstrictor thromboxanes relative to vasodilatory
prostaglandins has been demonstrated [64]. However, these
observations have been made in vivo, and while pathophysio-
logically relevant in the whole organism, they may not reflect
direct or primary actions of cyclosporine on transmembrane
signalling mechanisms involved in the eicosanoid cascade. An
alteration in the balance of cyclopentane derivatives (pros-
taglandins, thromboxanes, leukotrienes) elaborated is an ex-
pected consequence of inhibition of PLA2 activity. Measure-
ment of PGE2 or other eicosanoids serves as a marker of PLA2
activity whose inhibition appears to be a primary and direct
effect of cyclosporine administration. Irrespective of the de-
tailed profile of changes in arachidonic acid metabolites, the net
effect in vivo of their withdrawal from the glomerular microcir-
culation under vasoconstrictor hormone influence, has been
well studied, and this effect is augmented vasoconstriction [65].
Working formulation for cyclosporine-induced vasoconstriction
It is apparent that cyclosporine has the combined deleterious
effect of augmenting calcium signaling responses while at the
same time, through an apparently distinct mechanism, inhibit-
ing the counterbalancing release of vasodilatory eicosanoids in
contractile cells of the glomerular microcirculation and in
vascular smooth muscle cells (Fig. 7). This double effect
certainly constitutes an adequate biochemical basis for expect-
ing an augmented contractile response to vasoconstrictor hor-
mones. Indeed, videomicroscopic measurements of mesangial
and vascular smooth muscle contraction in culture have dem-
onstrated just such an effect of cyclosporine [36, 37, 66]. As yet,
it has not been fully determined whether enhancement of the
rise in intracellular calcium on the one hand, or inhibition of
vasodilatory prostaglandin production on the other hand,
makes the more important contribution to enhanced glomerular
vasoreactivity in vivo. In particular, inhibition of prostaglandin
production in and of itself (as occurs in the clinical setting of
administration of nonsteroidal anti-inflammatory drugs) is usu-
ally not sufficient to perturb glomerular hemodynamics or
systemic arterial blood pressure in the normal state, but has a
marked deleterious effect in the face of vasoconstrictor hor-
mone activation [65].
The formulation outlined in Figure 7, assumes even greater
importance with the recent appreciation that cyclosporine can
also augment the release of vasoconstrictor influences of local
endothelial origin in the glomerulus [16]. It should be noted that
a recent report by Takenaka et al. [67] suggested an important
contribution of cyclosporine-induced disruption of vasorelaxant
mediators of endothelial origin (most likely nitric oxide) in the
pathogenesis of overall renal vasoconstriction.
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Fig. 7. Working model for cyclosporine induced signaling perturba-
tions in mesangial cell vasoconstriction. Abbreviations are: CsA,
cyclosporine; PG, prostaglandins; GFR, glomerular filtration rate; BP.
blood pressure.
Therapeutic implications
Such a working formulation is particularly useful if it can
suggest potential strategies for preventing or ameliorating acute
cyclosporine-induced nephrotoxicity. In this regard, prosta-
glandin analogues have been shown to prevent or ameliorate
cyclosporine nephrotoxicity in animal models and are now the
subject of a clinical trial [68]. The reported salutary effect of
thromboxane synthetase inhibitors may be mediated in part
through diversion to increase production of vasodilatory pros-
taglandins [69, 70]. Fish oils rich in eicosapentanoic acids have
been shown to be of benefit in animal models and in preliminary
reports in the clinical setting as well [71]. It is thought that this
beneficial effect also relates to an improved balance between
vasodilatory prostaglandins and vasoconstrictor thromboxanes,
due to the high affinity of Omega-3 fatty acids for cyclo-
oxygenase and their inability to be used efficiently as substrate
for dienoic metabolites [72, 73J. However, other primary effects
on the more proximate phospholipase activities responsible for
calcium mobilization consequent to changes in membrane lipid
composition have not been excluded.
Given the effect of cyclosporine to raise intracellular calcium,
the potential role of calcium entry blockers warrants consider-
ation. It has been well described that the different classes of
calcium entry blockers generally have no effect on the acute
calcium signaling response to vasoconstrictor hormones in
mesangial cells and vascular smooth muscle cells in culture [33,
74—76]. In the mesangial cell, this is thought in part to reflect the
PG S relatively small contribution of voltage-sensitive calcium chan-
nels to this acute response. However, in the in vivo setting,
calcium entry blockers do have marked vasodilating effects at
all levels of the glomerular microcirculation, with particularly
apparent effects at the level of the afferent arteriole [77]. This
may be due to a long-term effect of these agents on calcium
entry pathways responsible for maintaining the fullness of
intracellular stores. It is therefore not surprising that nifedipine
and related drugs have emerged as useful agents in the treat-
ment of cyclosporine-induced hypertension and may also have
a potential role in ameliorating acute nephrotoxicity [78, 79]. It
should be noted that the use of these agents in combination with
cyclosporine may be complicated by important pharmacoki-
netic and pharmacodynamic interactions, one of which will be
considered below [80].
All of these strategies for ameliorating cyclosporine nephro-
toxicity depend on the use of additional agents to "undo"
unwanted and untoward toxic effects. A more elegant approach
would be to develop a derivative of cyclosporine which does
not share the same biochemical mechanisms involved in acute
nephrotoxicity. Such a strategy is entirely contingent upon the
assumption that biochemical mechanisms involved in immuno-
suppression can be dissociated from those involved in nephro-
toxicity and hypertension. This assumption has been tested for
the calcium signalling perturbations induced by cyclosporine
using selected analogues and metabolites [81]. In these studies
it was shown that an analogue of cyclosporine, cyclosporine H
(which substitutes the D form instead of the L form of methyl-
valine at position 11), devoid of immunosuppressive action,
induced changes in calcium signaling which were equivalent to
those induced by cyclosporin A. In contrast, metabolite 17
(n-hydroxylated at position 1) which binds to cyclophillin (see
below) and has some immunosuppressive action (depending on
assay system used ranging from 10 to 50%), was devoid of any
effect on calcium signaling [82, 83]. These results suggest that it
is indeed possible to dissociate at least one of the biochemical
mechanisms involved in nephrotoxicity from immunosuppres-
sive potential. Corresponding studies of phospholipase A2
inhibition are now required and will delineate the relative
contribution of this effect to overall nephrotoxicity, and deter-
mine whether this effect can also be dissociated from the
immunosuppressive potential. Thus, it may be possible to use
the mesangial cell in culture or other cell culture systems to
screen minute quantities of cyclosporine derivatives in an effort
to find those which may have an improved therapeutic poten-
Regulation of cellular cyclosporine accumulation and
interaction with P-glycoprotein
As part of the investigation of the effects of cyclosporine on
vasoconstrictor hormone signaling, studies have also been done
to examine the regulation of its accumulation in various target
cells. In particular, the potential role of P-glycoprotein in
regulating cyclosporine accumulation was examined.
P-glycoprotein is a 170 kDa transmembrane protein whose
expression in tumor cell lines confers resistance to a variety of
chemotherapeutic agents [84]. The gene encoding this protein
has been cloned, and based on the deduced amino acid se-
quence, it appears to represent an ATP driven drug effiux
vasoconstriCtiOn /s\ vasodilation
Normal
(GFR and BP normal)
$ vasoconstrictiOn 4, vasodilation
tial.
Skorecki et a!: Acute cyclosporine nephrotoxicity 7
Cell type
Fig. 8. Effect of verapamil on cyclosporine accumulation in renal and
non-renal cells. LLCPKI cells, rat mesangial cells (labeled MES) or a
non-renal cell line (Swiss 3T3) were incubated for one hour with
3H-dihydrocyclosponne and cyclosporin A in the presence (U) or
absence (El) of verapamil 200 jiM. The data represent the mean SEM
of six replicate wells in one experiment representative of three.
Adapted with permission from reference [851.
pump. Interest in the possibility that cyclosporine might inter-
act with P-glycoprotein came serendipitously from the obser-
vation that verapamil in high concentrations markedly in-
creased cyclosporine accumulation by renal cells in culture
(mesangial cells and LLC-PKJ cells), but not in an unrelated
nonrenal cell line (3T3 fibroblast) (Fig. 8) [85]. This effect
occurred at very high concentrations of verapamil which have
no implications for a pharmacodynamic interaction in the
clinical setting. However, at these high concentrations, vera-
pamil is known to inhibit P-glycoprotein and is used as a
prototypical inhibitor for in vitro pharmacological experiments
[841. Since many of the wide variety of drugs handled by
P-glycoprotein are lipophilic, natural plant products, it seemed
reasonable to consider cyclosporine as a candidate substrate for
this drug efflux pump. Indeed, it was shown that cellular
accumulation of cyclosporine varied reciprocally with expres-
sion of P-glycoprotein in three cell lines selected to express
varying defined levels of P-glycoprotein (Fig. 9, [85]). Cells
which had been selected to express the highest levels of
P-glycoprotein accumulated the least amount of cyclosporine.
Addition of verapamil at concentrations known to inhibit P-gly-
coprotein equalized the accumulation of cyclosporine among
the cell lines and raised its intracellular levels to those expected
in the absence of the drug pumping action of P-glycoprotein
(Fig. 9). Further studies also demonstrated that cyclosporine, at
therapeutically relevant concentrations, was an effective inhib-
itor of P-glycoprotein. This finding has motivated clinical trials
of cyclosporine as a chemosensitizer in drug resistant tumors,
which represents an exciting new therapeutic application en-
tirely separate from immunosuppression [86]. In this applica-
tion as well, nephrotoxicity might turn out to be a limiting
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Fig. 9. Cyclosporine accumulation in drug sensitive and multidrug
resistant CHO cells. Cells (AuxBl, sensitive, labeled AB; CHRA3
intermediate resistance, labeled A3; CHRC5 most resistant, labeled CS)
were incubated with 3H-dihydrocyclosporine (final activity: 13 pCi!
liter) and unlabeled cyclosporin A (20 ng/ml) for 1 hour in the presence
or absence of 100 jiM verapamil. The results represent the mean SEM
of three separate experiments, with six replicate wells in each experi-
ment. The asterisks denote a significant difference from the correspond-
ing control at the P < 0.01 level. Adapted with permission from
reference [85].
problem and would require comparison of the structural spec-
ificity for inhibition of P-glycoprotein with the structural spec-
ificity for both immunosuppression and mechanisms involved in
nephrotoxicity. Clinical trials using cyclosporine to overcome
multidrug resistance in renal cell carcinoma are already ongoing
[87] and will also provide a source of renal tissue from patients
who have been acutely exposed to high levels of cyclosporine
for purposes of further studying mechanisms involved in acute
nephrotoxicity.
Future directions
Clearly, further studies will be needed to clarify key elements
and details of the hypothesis raised in this editorial review, and
to extend them to the clinical arena. For example, various
strategies are available for distinguishing the cellular locus
whereby cyclosporine augments cytosolic calcium signaling. As
one example, quenching by external manganese of a fluores-
cence probe such as Indo-l loaded into the cell can serve as a
measurement of unidirectional calcium influx [881 and can be
used as a test of the effect of cyclosporine in this process.
Various pharmacological probes, such as thapsigargin [89], are
now able to distinguish 1P3 sensitive versus 1P3 insensitive
calcium stores. If cyclosporine is indeed shown to alter mem-
brane calcium permeability, then it would be necessary to
determine whether the reported salutary effect of fish oils to
ameliorate cyclosporine nephrotoxicity is mediated in part by
reversal of this effect through a change in membrane lipid
composition, in addition to the well described effects of fish oils
on eicosanoid metabolism [90].
The recent discovery of FK-506, a fungal metabolite whose
immunosuppressive profile is similar to that of cyclosporine,
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suggests the forthcoming emergence of a whole class of similar
agents. The ability to preserve therapeutic potential (immuno-
suppression or chemosensitization) in a manner which can be
dissociated from toxicity (nephrotoxicity and hypertension),
will be a key factor in the potential utility of such compounds.
An understanding of the molecular and biochemical basis for
both immunosuppression and nephrotoxicity, and the availabil-
ity of model systems for testing small quantities of such
compounds will aid in this evaluation. In this regard, using
preparative HPLC applied to the bile of liver transplant recip-
ients, it has been possible to extract, purify and test previously
undescribed metabolites of cyclosporine, which appear to have
promising immunosuppressive action, but without sharing some
of the nephrotoxic actions of parent compound [91]. Compari-
son of the effect of cyclosporine analogues and related com-
pounds on signalling pathways in the mesangial cell on the one
hand, with their effects on kidney function in vivo on the other
hand, will also afford the opportunity to validate or refute
elements of the hypothesis raised in this editorial review. In
particular, both cyclosporine and FK 506are inhibitors of T cell
activation and both bind to and inhibit structurally distinct
cellular proteins (members of the "immunophillin" class of
cytosolic proteins [92]) which share a common enzymatic
function (peptidyl-prolyl cis-trans isomerase activity). The
T-cell receptor (TCR) is stimulated by a foreign antigen pre-
sented by a major histocompatibility (MHC) molecule on the
surface of an antigen presenting cell which then results in the
activation of specific nuclear transcription factors such as
nuclear factor of activated T cells (NF-AT). These regulate
transcription of T-cell activation genes such as 11-2. Both
cyclosporine and FK506 are potent inhibitors of this TCR-
mediated signal transduction pathway. Therefore, it is likely
that the immunophillins serve as key regulators of TCR-medi-
ated signal transduction which is disrupted by cyclosporine and
related compounds.
This also raises intriguing possibilities to explain the effects of
cyclosporine on calcium transport and phospholipase activation
[93]. In particular, cis-trans isomerization of peptidyl-prolyl
bonds is thought to govern conformation of key transmembrane
transports and signal transduction proteins [94]. Therefore, it
will be of importance to determine whether inhibition of this
enzymatic activity has any relation to the transmembrane signal
transduction perturbing effects of cyclosporine or related com-
pounds. This brings us full circle and highlights the utility of
examining pathophysiologic states, such as acute cyclosporine
nephrotoxicity, as disorders of transmembrane signal transduc-
tion in the kidney.
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